|
|
|
Alexion Licenses Novel Display System
|
Business New Haven
10/15/2001
By: BNH
|
CHESHIRE - Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) earlier this month announced that it had acquired exclusive worldwide commercial rights to a new technology that allows the rapid discovery of new antibody drug candidates.
The technology, which is protected by U.S. Patent No. 5,766,905, entitled “Cytoplasmic Bacteriophage Display System,” involves a new application of the T7Select Phage Display System from Novagen. The new technology is an in-vitro antibody discovery tool based on the display of combinatorial antibody libraries on the surface of the bacteriophage T7. Alexion's license covers human therapeutic antibodies.
Financial terms were not disclosed.
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
